Basic information
Biomarker: p16
Histology type: endometrial carcinoma
Cohort characteristics
Country: Korea
Region: Daegu
Study type: retrospective study
Followed up time :
Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
---|---|---|---|---|---|---|---|---|
124 | malignant lesions | 36 | benign lesions | 62 | precancerous lesions | 26 |
Sample information
Conclusion: Our observations suggest that stromal p16 expression is involved in the development and progression of endometrial carcinoma, and raise the possibility that p16 overexpression in the peritumoral stroma is associated with aggressive oncogenic behavior of endometrial SC.
Sample type : tissue
Sample method: immunohistochemistry
Expression pattern : stromal p16 overexpression(scores ≥ 6)
Expression elevation: The estimated percentages were categorized as follows: less than 10% (score 0), 10% to 24% (score 1), 25% to 50% (score 2), or 50% or more (score 3). The staining intensity was graded as follows: negative (score 0), weak (score 1), moderate (score 2), or strong (score 3). The subcellular location of p16-positive signals (nuclear or cytoplasmic) was also estimated. The final score was calculated as the product of the percentage and staining intensity, resulting in scores of 0, 1, 2, 3, 4, 6, and 9.
Disease information
Related information
Funtion Uniprot: Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein.
UniProt ID: Q8N726
UniProt Link: https://www.uniprot.org/uniprotkb/Q8N726/entry#function
Biological function from UniProt: Apoptosis, Cell cycle, rRNA processing, Transcription, Transcription regulation, Ubl conjugation pathway
Molecular function from UniProt:
Subcellular UniProt: #Mitochondrion #Nucleus
Alternative name from UniProt:
Caution: The proteins described here are encoded by the gene CDKN2A, but are completely unrelated in terms of sequence and function to cyclin-dependent kinase inhibitor 2A (AC P42771) which is encoded by the same gene.
Recommended name: Tumor suppressor ARF
Gene name from HGNC: CDKN2A (ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf)
HPA class: Cancer-related genes Disease related genes Human disease related genes Plasma proteins
AlphaFold DB: Q8N726
AlphaFold Link: https://alphafold.ebi.ac.uk/entry/Q8N726
HPA link: https://www.proteinatlas.org/ENSG00000147889-CDKN2A
Tissue specificity RNA from HPA: Tissue enhanced (choroid plexus, pituitary gland)
Tissue expression from HPA: Mainly nuclear expression in most tissues.
Single cell type specificity Cell type enhanced (Late spermatids, Pancreatic endocrine cells, Early spermatids, Respiratory ciliated cells, Basal respiratory cells, Club cells)
Immune cell specificity: Immune cell enhanced (T-reg)
Subcellular summary HPA Located in Nucleoli (Single cell variability)
Cancer prognostic summary HPA Prognostic marker in endometrial cancer (unfavorable), renal cancer (unfavorable), liver cancer (unfavorable) and head and neck cancer (favorable)
Pathology link: https://www.proteinatlas.org/ENSG00000147889-CDKN2A/pathology
Pathology endo: https://www.proteinatlas.org/ENSG00000147889-CDKN2A/pathology/endometrial+cancer
OMIM: 600160
OMIM link2: https://www.omim.org/entry/600160
HGNC ID: HGNC:1787
HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1787